Induction of neural progenitor cells, oligodendrocyte progenitor cells, and oligodendrocytes by stem cell differentiation using landmark transcription factors
AssigneeAllele Biotechnology & Pharmaceuticals, Inc.
InventorsJiwu WANG, Yuhui NI, Yuanyuan ZHAO
Life of this patent
Estimating the term…
Abstract
A novel method of inducing neural progenitor cells, oligodendrocyte progenitor cells, oligodendrocytes from human iPSCs at an unprecedented efficiency and functionality. The core of the invention is the use of experimentally discovered transcription factors at multiple critical differentiation decision points along a pluripotent to ectoderm, neural ectoderm to NPCs to OPCs to oligodendrocytes pathway in a previously unknown manner.
Claims39
A method for inducing differentiation of an induced pluripotent stem cells (iPSCs) and/or embryonic stem cells (ESCs) into neural progenitor cells (NPCs) said method comprising:
- a) plating iPSCs and/or ESCs on a coated, non-tissue treated, culturing vessel in medium;
- b) transfecting the cells of step a) with mRNA encoding one or more cell-fate factors as individual mRNA or combined mRNA;
- and
- c) culturing said iPSCs and/or ESCs of step b) until the cells differentiate to NPCs.
19-31. (canceled)
A method for generating oligodendrocytes from OPCs comprising:
- a) plating OPCs on coated cell culture vessels in medium;
- and
- b) culturing the cells of step a) until cells appear with tree branch-looking processes or produce myelin basic protein (MBP).
(canceled)
A method for inducing differentiation of stem cell into NPCs, OPCs, oligodendrocytes sequentially or directly said method comprising:
- a) plating iPSCs and/or ESCs on a coated culturing vessel, wherein the iPSCs and/ESCs are seeded using about 70,000 cells to about 14,000,000 cells per culture flask or culture well-plate in medium comprising containing minimal media-alpha (MEMa), or Dulbecco's Modified Eagle Medium:
- Nutrient Mixture F-12 (DMEM/F12), or DMEM with B27 supplement all with knock out replacement serum (KSR);
- b) transfecting the cells of step a) with mRNA encoding cell fate factors selected from the group consisting of one or more of Ngn2, Pax6, Sox2, Brn2 and FoxO family factors as individual mRNA or combined mRNA transfection;
- c) culturing said iPSCs and/or ESCs of step b) until the cells differentiate to NPCs.
- d) isolating the NPCs from step c):
- e) plating NPCs on coated cell culture vessels, wherein the NPCs are seeded using about 70,000 cells to about 14,000,000 cells per culture flask or culture well-plate in medium comprising MEMa, or DMEM/F12, or DMEM, all with KSR and one or more of the medium supplements selected from the group consisting of ascorbic acid, SAG, PDGF, HGF, IGF1, T3, insulin, RA, B27, CAMP and biotin;
- f) transfecting the cells of step e) with one or more of the group consisting of Oligo2, NKX2.2, SOX10, and Oligo1 mRNA individually or in combination using transfection reagents;
- g) repeating the transfection of step e) at least two more times;
- h) culturing the cells of step g) until the morphology of the cells change from the morphology of an NPC cell to an OPC cell;
- i) isolating the OPCs from step h);
- j) plating the isolated OPCs from step j) onto coated cell culture vessels, wherein the OPCs are seeded using about 70,000 cells to about 14,000,000 cells per culture flask or culture well-plate in medium comprising MEMa, or DMEM/F12, or DMEM, all with KSR and one or more of the medium supplements selected from the group consisting of ascorbic acid, N2, B27, biotin, Cam, T3, and insulin;
- and
- K) culturing the cells for at least about 1 week until oligodendrocytes cells appear with tree branch-looking processes and/or produce myelin basic protein (MBP).
The method according to claim 27, wherein a six-well culture plate is used and the transfection dose is at doses of mRNA of about 10 ng/cell-fate factor to about 200 ng/cell-fate factor.
(canceled)
Dependencies are inferred from the claim text.